

IE Technology Appraisals (medicines): Formulary Adherence 2017/2018

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals.

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision due (90 days)	Date of local decision made	Time to implement days
TA434 - Elotuzumab for previously treated multiple myeloma	22 nd March 2017	NICE was unable to make a recommendation about the use in the NHS of elotuzumab – appraisal terminated		N/A		19/04/2017	28
TA435 – Tenofovir alafenamide for treating chronic hepatitis B	22 nd March 2017	NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide – appraisal terminated		N/A		19/04/2017	28
TA436 – Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer	22 nd March 2017	NICE was unable to make a recommendation about the use in the NHS of bevacizumab– appraisal terminated		N/A		19/04/2017	28
TA437 - Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy	22 nd March 2017	NICE was unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine & rituximab – appraisal terminated		N/A		19/04/2017	28
TA438 - Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	29 th March 2017	NICE was unable to make a recommendation about the use in the NHS of alectinib – appraisal terminated		N/A		19/04/2017	21
TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer	29 th March 2017	Evidence-based recommendations on cetuximab and panitumumab for previously untreated RAS wild-type metastatic colorectal cancer in adults. NHSE Commissioned	Y		27/06/2017	19/04/2017	21
TA340 - Ustekinumab for treating active psoriatic arthritis	3 rd March 2017 (updated)	Evidence-based recommendations on ustekinumab for treating active psoriatic arthritis in adults. CCG Commissioned	Y		01/06/2017	19/04/2017	46
TA240 Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer	29 th March 2017 (updated)	NICE was unable to make a recommendation about the use in the NHS of panitumumab with 5- fluorouracil folinic acid and irinotecan – appraisal terminated		N/A	27/06/2017	19/04/2017	21
TA180 (updated) - Ustekinumab for the treatment of adults with moderate to severe psoriasis	3 rd March 2017 (updated)	Evidence-based recommendations on ustekinumab for treating psoriasis in adults CCG Commissioned	Y		01/06/2017	19/04/2017	46
TA440 - Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine	26 th April 2017	Evidence-based recommendations on pegylated liposomal irinotecan for treating pancreatic cancer in adults (not recommended)		N/A	25/07/2017	21/06/2017	56
TA441 - Daclizumab for treating relapsing–remitting multiple sclerosis	26 th April 2017	Evidence-based recommendations on daclizumab for treating relapsing–remitting MS. NHSE Commissioned	Y		25/07/2017	21/06/2017	56

TA442 - Ixekizumab for treating moderate to severe plaque psoriasis	26 th April 2017	Evidence-based recommendations on Ixekizumab for moderate to severe plaque psoriasis in adults. NHSE Commissioned	Y		25/07/2017	21/06/2017	56
TA443 - Obeticholic acid for treating primary biliary cholangitis	26 th April 2017	Evidence-based recommendations on obeticholic acid for treating primary biliary cholangitis in adults. NHSE Commissioned	Y		25/07/2017	21/06/2017	56
TA444 - Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy	24 th May 2017	NICE was unable to make a recommendation about the use in the NHS of afatinib for treating advanced or metastatic squamous non-small-cell lung cancer after platinum based chemotherapy – appraisal terminated		N/A	22/08/2017	21/06/2017	28
TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs	24 th May 2017	Evidence-based recommendations on certolizumab pegol and secukinumab for treating active psoriatic arthritis in adults. CCG Commissioned	Y		22/08/2017	21/06/2017	28
TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	28 th June 2017	Evidence-based recommendations on brentuximab vedotin for treating CD30-positive Hodgkin lymphoma in adults. NHSE Commissioned	Y		26/09/2017	19/07/2017	21
TA447 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer	28 th June 2017	Evidence-based recommendations on pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NHSE Cancer Drugs Fund	Y		26/09/2017	19/07/2017	21
TA448 - Etelcalcetide for treating secondary hyperparathyroidism	28 th June 2017	Evidence-based recommendations on etelcalcetide for treating secondary hyperparathyroidism in adults with chronic CKD on haemodialysis. CCG commissioned	Y		26/09/2017	19/07/2017	21
TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	28 th June 2017	Evidence-based recommendations on everolimus and sunitinib for treating neuroendocrine tumours in adults. NHSE Commissioned	Y		26/09/2017	19/07/2017	21
TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	28 th June 2017	Evidence-based recommendations on blinatumomab for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults. NHSE Commissioned	Y		26/09/2017	19/07/2017	21
TA451 - Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	28 th June 2017	Evidence-based recommendations on ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults. NHSE Commissioned	Y		26/09/2017	19/07/2017	21
TA452 - Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation	5 th July 2017	NICE was unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation. (terminated appraisal)		N/A	03/10/2017	20/09/2017	77
TA453 - Bortezomib for treating multiple myeloma after second or subsequent relapse	5 th July 2017	NICE was unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse. (terminated appraisal)		N/A	03/10/2017	20/09/2017	77
TA454 - Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	5 th July 2017	NICE was unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma. (terminated appraisal)		N/A	03/10/2017	20/09/2017	77
TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people	12 th July 2017	Evidence-based recommendations on adalimumab, etanercept and ustekinumab for plaque psoriasis in children and young people. NHSE Commissioned	Y		10/10/2017	20/09/2017	70
TA456 - Ustekinumab for moderately to severely active Crohn's disease after previous treatment	12 th July 2017	Evidence-based recommendations on ustekinumab for previously treated moderately to severely active Crohn's disease in adults. CCG commissioned	Y		10/10/2017	20/09/2017	70

TA457 - Carfilzomib for previously treated multiple myeloma	19 th July 2017	Evidence-based recommendations on carfilzomib for treating multiple myeloma in adults. NHSE Commissioned	Y		17/10/2017	20/09/2017	63
TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and taxane	19 th July 2017	Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2) -positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane. NHSE Commissioned	Y		17/10/2017	20/09/2017	63
TA459 - Collagenase clostridium histolyticum for treating Dupuytren's contracture	26 th July 2017	Evidence-based recommendations on collagenase clostridium histolyticum (Xiapex) for treating Dupuytren's contracture in adults. CCG commissioned	Y		24/10/2017	20/09/2017	56
TA460 – Adalimumab and dexamethasone for treating non-infectious uveitis	26 th July 2017	Evidence-based recommendations on adalimumab and dexamethasone for treating non-uveitis in adults. Adalimumab NHSE Commissioned Dexamethasone CCG commissioned	Y		24/10/2017	20/09/2017	56
TA461 – Roflumilast for treating chronic obstructive pulmonary disease	26 th July 2017	Evidence-based recommendations on roflumilast for treating chronic obstructive pulmonary disease in adults with chronic bronchitis. CCG commissioned	Y		24/10/2017	20/09/2107	56
TA462 – Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	26 th July 2017	Evidence-based recommendations on nivolumab for treating relapsed or refractory classical Hodgkin lymphoma in adults. NHSE Commissioned	Y		24/10/2017	20/09/2017	56
TA463 – Cabozantinib for previously treated advanced renal cell carcinoma.	9 th August 2017	Evidence-based recommendations on Cabozantinib for previously treated advanced renal cell carcinoma. NHSE Commissioned	Y		07/11/2017	20/09/2017	42
TA464 – bisphosphonates for treating osteoporosis	9 th August 2017	Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis. CCG commissioned	Y		07/11/2017	20/09/2107	42
TA465 – Olaratumab in combination with doxorubicin for treating advanced softy tissue sarcoma	9 th August 2017	Evidence-based recommendations on olaratumab plus doxorubicin for advanced soft tissue sarcoma in adults. NHSE Commissioned	Y		07/11/2017	20/09/2017	42
TA466 – Baricitinib for moderate to severe rheumatoid arthritis	9 th August 2017	Evidence-based recommendations on baricitinib for moderate to severe rheumatoid arthritis in adults. CCG commissioned	Y		07/11/2017	20/09/2107	42
TA190 – Pemetrexed for the maintenance treatment of non-small-cell lung cancer	10 th August 2017 (updated)	Evidence-based recommendations on pemetrexed disodium the maintenance treatment of non-small-cell lung cancer. NHSE Commissioned	Y		08/11/2017	20/09/2017	41
TA160 – raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women	9 th August 2017 (updated in line with TA464)	Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.	Y		07/11/2017	20/09/2107	42
TA161 – Alendronate, etidronate, risedronate, raloxifene, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women	9 th August 2017 (updated)	Evidence-based recommendations on – guidance partially updated by NICE's technology appraisal guidance on bisphosphonates for treating osteoporosis	Y		07/11/2017	20/009/2017	42
TA467 – Holoclar for treating limbal stem cell deficiency after eye burns	16 th August 2017	Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns. NHSE Commissioned	Y		14/11/2017	20/09/2017	35

TA468 – Methylnaltrexone bromide for treating opioid induces constipation	23 rd August 2017	NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid induced constipation – appraisal terminated		N/A	21/11/2017	20/09/2017	28
TA469 – Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia	23 rd August 2017	NICE was unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia appraisal terminated		N/A	21/11/2017	20/09/2017	28
TA470 – Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia	23 rd August 2017	NICE was unable to make a recommendation about the use in the NHS of Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia. Appraisal terminated .		N/A		20/09/2017	28
TA471 –Eluxadoline for treating irritable bowel syndrome with diarrhoea	30 th August 2017	Evidence-based recommendations on Eluxadoline for treating irritable bowel syndrome with diarrhoea in adults. CCG commissioned	Y		28/11/2017	20/09/2017	21
TA472 – Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab	30 th August 2017	Evidence-based recommendations on Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. NHSE Cancer Drugs Fund	Y		28/11/2017	20/09/2017	21
TA473 – Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck	31 st August 2017	Evidence-based recommendations on Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NHSE Commissioned	Y		29/11/2017	20/09/2017	20
TA474 – Sorafenib for treating advanced hepatocellular carcinoma	6 th September 2017	Evidence-based recommendations on Sorafenib for treating advanced hepatocellular carcinoma. NHSE Commissioned	Y		05/12/2017	18/10/2017	42
TA475- Dimethyl fumarate for treating moderate to severe plaque psoriasis	6 th September 2017	Evidence-based recommendations on Dimethyl fumarate for treating moderate to severe plaque psoriasis CCG Commissioned (Blueteq form)	Y		05/12/2017	18/10/2017	42
TA476 – Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer	6 th September 2017	Evidence-based recommendations on Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer NHSE commissioned	Y		05/12/2017	18/10/2017	42
TA439 – Cetuximab and panitumumab for previously untreated metastatic colorectal cancer	25 th September 2017 (updated)	Evidence-based recommendations on cetuximab and panitumumab for previously untreated RAs wild-type metastatic colorectal cancer in adults. NHSE commissioned	Y		24/12/2017	18/10/2018	23
TA428 – Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy	12 th September 2017(updated)	Evidence-based recommendations on Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. NHSE commissioned	Y		11/12/2017	18/10/2017	36
TA366 – Pembrolizumab for advanced melanoma not previously treated with ipilimumab	12 th September 2017 (updated)	Evidence-based recommendations on pembrolizumab for advanced melanoma not previously treated with ipilimumab NHSE commissioned	Y		11/12/2017	18/10/2017	36
TA357 - Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab	12 th September 2017 (updated)	Evidence-based recommendations on Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. NHSE commissioned	Y		11/12/2017	18/10/2017	36
TA477 – Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee	4 th October 2017	Evidence-based recommendations on Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee. NHSE commissioned	Y		02/01/2018	15/11/2017	42

TA478 – Brentuximab cedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma	4 th October 2017	Evidence-based recommendations on Brentuximab cedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma. NHSE commissioned	Y		02/01/2018	15/11/2017	42
TA479 – Reslizumab for treating severe eosinophilic asthma	4 th October 2017	Evidence-based recommendations on Reslizumab for treating severe eosinophilic asthma. NHSE commissioned	Y		02/01/2018	15/11/2017	42
TA480 – Tofacitinib for moderate to severe rheumatoid arthritis	11 th October 2017	Evidence-based recommendations on Tofacitinib for moderate to severe rheumatoid arthritis. CCG Commissioned (Blueteq form)	Y		09/01/2018	15/11/2017	35
TA481 – Immunosuppressive therapy for kidney transplant in adults Replaces TAG85	11 th October 2017	Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab, immediate-release tacrolimus, mycophenolate mofetil), rabbit anti-human thymocyte immunoglobulin, prolonged-release tacrolimus, mycophenolate sodium, sirolimus, everolimus and belatacept. NHSE commissioned	Y		09/01/2018	15/11/2017	35
TA482 – Immunosuppressive therapy for kidney transplant in children and young people. Replaces TAG99	11 th October 2017	Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab, immediate-release tacrolimus, mycophenolate mofetil, rabbit anti-human thymocyte immunoglobulin, prolonged-release tacrolimus, mycophenolate sodium, sirolimus, everolimus and belatacept. NHSE commissioned	Y		09/01/2018	15/11/2017	35
TA483- Nivolumab for previously treated squamous non-small-cell lung cancer	1 st November 2017	Evidence-based recommendations on nivolumab for locally advanced or metastatic squamous non-small-cell lung cancer in adults. NHSE Cancer Drugs Fund	Y		30/01/2018	17/01/2018	77
TA484 – Nivolumab for previously treated non-squamous non-small-cell lung cancer	1 st November 2017	Evidence-based recommendations on nivolumab for locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy. NHSE Cancer Drugs Fund	Y		30/01/2018	17/01/2018	77
TA485 – Sarilumab for moderate to severe rheumatoid arthritis	1 st November 2017	Evidence-based recommendations on Sarilumab for moderate to severe rheumatoid arthritis CCG Commissioned (Blueteq form)	Y		30/01/2018	17/01/2018	77
TA486 - Aflibercept for treating choroidal neovascularisation	1 st November 2017	Evidence-based recommendations on Aflibercept for treating choroidal neovascularisation. NHSE commissioned	Y		30/01/2018	17/01/2018	77
TA487 – Venetoclax for treating chronic lymphocytic leukaemia	8 th November 2017	Evidence-based recommendations on Venetoclax for treating chronic lymphocytic leukaemia. NHSE Cancer Drugs Fund	Y		06/02/2018	17/01/2018	70
	15 th November 2017	Evidence-based recommendations on Regorafenib for previously treatable unresectable or metastatic gastrointestinal stromal tumours. NHSE commissioned	Y		13/02/2018	17/01/2018	63
TA489 – Vismodegib for treating basal cell carcinoma	22 nd November 2017	Evidence-based recommendations on Vismodegib for treating basal cell carcinoma. NHSE commissioned	Y		20/02/2018	17/01/2018	56

Nice Guidance - local summary 2017 - 2018

TA490 – Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy.	22 nd November 2017	Evidence-based recommendations on Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy. NHSE commissioned	Y		20/02/2018	17/01/2018	56
TA491 - Ibrutinib for treating Waldenstrom's macroglobulinaemia	22 nd November 2018	Evidence-based recommendation on Ibrutinib for treating Waldenstrom's macroglobulinaemia in adults after at least 1 previous therapy. NHSE Cancer Drugs Fund	Y		20/02/2018	17/01/2018	56
TA458 – Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane	20 th November 2017 (updated, replaces TA371)	Evidence-based recommendation on trastuzumab emtansine for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane. NHSE commissioned	Y		18/02/2018	17/01/2018	54
TA462 – Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	7 th November 2017 (updated)	Evidence-based recommendation on Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma. NHSE commissioned	Y		05/02/2018	17/01/2018	71
TA417 – Nivolumab for previously treated advanced renal cell carcinoma	7 th November 2017 (updated)	Evidenced-based recommendations on nivolumab for previously treated advanced renal cell carcinoma in adults. NHSE commissioned	Y		05/02/2018	17/01/2018	71
TA492 – Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable.	6 th December 2017	Evidenced-based recommendations on atezolizumab for locally advanced or metastatic urothelial carcinoma in adults NHSE Cancer Drugs Fund .	Y		06/03/2018	17/01/2018	42
TA493 – Cladribine tablets for treating relapsed-remitting multiple sclerosis	6 th December 2017	Evidenced-based recommendations on Cladribine tablets for treating highly active relapsing-remitting multiple sclerosis in adults. NHSE commissioned	Y		06/03/2018	17/01/2018	42
TA494 – Naltrexone-bupropion for managing overweight and obesity	12 th December 2017	Evidence-based recommendations on Naltrexone-bupropion for managing overweight and obesity in adults. Not recommended within its marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity.		N/A	12/03/2018	17/01/2018	36
TA495 – Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.	20 th December 2017	Evidence-based recommendations on palbociclib as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults. NHSE commissioned	Y		20/03/2018	17/01/2018	28
TA496- Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.	20 th December 2017	Evidence-based recommendations on ribociclib as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults. NHSE commissioned	Y		20/03/2018	17/01/2018	28
TA497 - Golimumab for treating non-radiographic axial spondyloarthritis	10 th January 2018	Evidence-based recommendations on Golimumab for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked. CCG Commissioned (Blueteq form)	Y		10/04/2018	21/02/2018	42

TA498 – Lenvatinib with everolimus for previously treated advanced renal cell carcinoma	24 th January 2018	Evidence-based recommendations on lenvatinib with everolimus for previously treated advanced renal cell carcinoma in adults. NHSE commissioned	Y		24/04/2018	21/02/2018	28
TA499 - Glecaprevir-pibrentasvir for treating chronic hepatitis C	24 th January 2018	Evidence-based recommendations on glecaprevir-pibrentasvir for treating chronic hepatitis C in adults. NHSE commissioned	Y		24/04/2018	21/02/2018	28
TA500 – ceritinib for untreated ALK-positive non-small-cell lung cancer	24 th January 2018	Evidence-based recommendations on ceritinib for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults. NHSE commissioned	Y		24/04/2018	21/02/2018	28
TA501- Intrabeam radiotherapy system for adjuvant treatment of early breast cancer	31 st January 2018	Evidence-based recommendations on using intrabeam radiotherapy during breast-conserving surgery in adults. Not recommended as an option by NICE		N/A	01/05/2018	21/02/2018	21
TA502- Ibrutinib for treating relapsed or refractory mantle cell lymphoma	31 st January 2018	Evidence-based recommendations on ibrutinib for treating relapsed or refractory mantle cell lymphoma in adults. NHSE commissioned	Y		01/05/2018	21/02/2018	21
TA503- Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer	31 st January 2018	Evidence-based recommendations on fulvestrant for treating locally advanced or metastatic (secondary), oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before. Not recommended as an option by NICE		N/A	01/05/2018	21/02/2018	21
TA504 – Pirfenidone for treating idiopathic pulmonary fibrosis	6 th February 2018	Evidence-based recommendations on pirfenidone for idiopathic pulmonary fibrosis. (replaces NICE TA282). NHSE commissioned	Y		07/05/2018	21/03/2018	43
TA505 – Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	7 th February 2018	Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults. NHSE Cancer Drugs Fund.	Y		08/05/2018	21/03/2018	42
TA506 – Lesinurad for treating chronic hyperuricaemia in people with gout	7 th February 2018	Evidence-based recommendations on lesinurad for treating chronic hyperuricaemia in people with gout. Not recommended as an option by NICE		N/A	08/05/2018	21/03/2018	42
TA507- Sofosbuvir-velpatasvir for treating chronic hepatitis C	21 st February 2018	Evidence-based recommendations on s Sofosbuvir-velpatasvir for treating chronic hepatitis C in adults. NHSE commissioned	Y		22/05/2018	21/03/2018	28
TA160 – Raloxifene for the primary prevention of osteoporosis fragility fractures in postmenopausal women.	7 th February 2018 (last update)	Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.		N/A	08/05/2018	21/03/2018	42
TA161 – Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women	7 th February 2018 (last update)	Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis. -		N/A	08/05/2018	21/03/2018	42

Total	69	20			
	% "Yes"	% "No"			Average implementation time (days)
Adherence statistics for 2017 - 2018	78%	22%			42